About
Dr. George A. Scangos has served on the Agilent board since January 2011, where he chairs the Compensation Committee and serves on the Nominating/Corporate Governance Committee. He retired as Chief Executive Officer of Vir Biotechnology in April 2023 and previously served as CEO of Biogen Inc. (2010-2017), President and CEO of Exelixis, Inc. (1996-2010), and President of Bayer Biotechnology (1993-1996). He is a co-founder and Chairperson of Rezo Therapeutics and has served on the board of Voyager Therapeutics, Inc. since May 2023.
Roles
Agilent Technologies, Inc.
Director (Chair, Compensation Committee) · Current role
January 2011–present
Vir Biotechnology, Inc.
Chief Executive Officer · Retired April 2023; also a director January 2017 - May 2025
—
Biogen Inc.
Chief Executive Officer and director
July 2010 - January 2017
Exelixis, Inc.
President and Chief Executive Officer
1996 - July 2010
Bayer Biotechnology
President
1993 - 1996
Johns Hopkins University
Professor of Biology · Currently Adjunct Professor of Biology
1981 -
External Roles
Voyager Therapeutics, Inc.
Director
May 2023 - present
Rezo Therapeutics, Inc.
Co-founder and Chairperson of the Board
May 2023 - present
Director Compensation
FY 2025Cash retainer
$105,000
ComponentBoard and committee cash retainers earned in FY2025
Compensation Committee Chair retainer
$20,000
Stock awards
$220,426
ComponentAnnual stock grant, ASC 718 grant-date fair value (1,819 shares)
Total
$345,426
Also at Agilent Technologies, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.